Methods for guiding therapy decisions in seizure disorders
AssigneeMayo Foundation for Medical Education and Research
InventorsCharles L. Howe, Benjamin D. Clarkson, Shailaja Kunda, Reghann G. LaFrance-Corey, Eric T. Payne
Life of this patent
Estimating the term…
Abstract
Materials and methods for identifying subjects as being likely or not likely to respond to an interleukin-1β receptor antagonist (IL-1RA) therapy for a seizure disorder, as well as materials and methods for treating subjects identified as being likely to respond to an IL-1RA therapy for a seizure disorder, are provided herein.
Claims17
A method for treating a subject having a seizure disorder, said method comprising determining that the subject has decreased IL-1RA function as compared to the level of IL-1RA function in corresponding normal subjects who do not have the seizure disorder, and administering to the subject a treatment that attenuates IL-1R inflammatory signaling, wherein said treatment comprises one or more of anakinra, EBI-005, and MEDI-8968.
A method for treating a subject having a seizure disorder, comprising identifying the subject as having a level of functional IL-1RA antagonism that is decreased below a predetermined threshold level of functional IL-1RA antagonism, and administering to the subject a treatment that attenuates IL-1R inflammatory signaling, wherein said treatment is selected from the group consisting of anakinra, EBI-005, and MEDI-8968.
Dependencies are inferred from the claim text.